NBS 10
Alternative Names: AMR-001; CLBS 10; NBS10Latest Information Update: 19 Sep 2022
At a glance
- Originator Amorcyte
- Developer Lisata Therapeutics
- Class Haematopoietic stem cells therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain injuries
- Discontinued Myocardial infarction
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 28 Apr 2018 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
- 15 Mar 2016 Caladrius out-licenses CD34 ischemic repair technnology to SPS Cardio LLC